

Item 8.01. Other Events.

On December 10, 2017, Immune Design Corp. issued a press release reporting new data from its randomized Phase 2 clinical trial of G100 plus low-dose radiation, with or without Keytruda® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with follicular non-Hodgkin's lymphoma. The data were presented at the 59th American Society of Hematology (ASH) Annual meeting in Atlanta, Georgia on Sunday, December 10, 2017. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
-------------------	-------------

99.1	<u>Press Release, dated December 10, 2017.</u>
------	--

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMMUNE DESIGN CORP.

By: /s/ Carlos Paya, M.D., Ph.D.

Carlos Paya, M.D., Ph.D.

President and Chief Executive Officer

Dated: December 13, 2017